Mergerplay - Älteste Beiträge zuerst (Seite 10)
eröffnet am 02.11.17 21:13:52 von
neuester Beitrag 02.11.22 16:26:10 von
neuester Beitrag 02.11.22 16:26:10 von
Beiträge: 353
ID: 1.266.182
ID: 1.266.182
Aufrufe heute: 0
Gesamt: 38.415
Gesamt: 38.415
Aktive User: 0
ISIN: US30048L2034 · WKN: A3DL69
0,1860
EUR
0,00 %
0,0000 EUR
Letzter Kurs 05.10.22 L&S Exchange
Neuigkeiten
18.12.23 · Business Wire (engl.)  |
12.12.23 · Business Wire (engl.) |
12.12.23 · Business Wire (engl.) |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5700 | +55,23 | |
| 5,4500 | +41,56 | |
| 141,00 | +41,00 | |
| 1,1500 | +34,98 | |
| 1,0000 | +33,33 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 7,0000 | -12,50 | |
| 1,8700 | -12,62 | |
| 12,150 | -12,72 | |
| 35,69 | -13,71 | |
| 5,2500 | -19,23 |
Feedback
Am Freitag 24.8. wurden grössere Positionen gehandelt von 111500 , 67110 und 19550
das Interesse an EVFM hat zu genommen.
das Interesse an EVFM hat zu genommen.
Antwort auf Beitrag Nr.: 58.543.010 von fypet am 27.08.18 15:22:18Und jetzt ist viel Luft nach oben - zumal in den USA wieder fette kaufblöcke zu sehen waren.
Efvm startet
Efvm startet
Antwort auf Beitrag Nr.: 58.556.687 von Stingrey am 29.08.18 07:37:36EVFM wird anscheinend in ein paar Tagen den Widerstand von $3,75 erreichen,
wurde ja in den letzten Monate auch grundlos massakriert.
JETZT GIBT ES KEIN Halten MEHR, schätzungsweise 150Mio Marktkapitalisierung.
wurde ja in den letzten Monate auch grundlos massakriert.
JETZT GIBT ES KEIN Halten MEHR, schätzungsweise 150Mio Marktkapitalisierung.
Antwort auf Beitrag Nr.: 58.563.449 von fypet am 29.08.18 18:35:29
Rise in Prevalence of STDs Reported by CDC Supports Continued Development of Novel Solutions, Like Evofem's Product in Development, Amphora®, for the Prevention of Chlamydia
Mittwoch, 29.08.2018 15:00 von PR Newswire
PR Newswire
SAN DIEGO, Aug. 29, 2018
SAN DIEGO, Aug. 29, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, believes that new data recently released by the Centers for Disease Control and Prevention (CDC) on the increasing rates of sexually transmitted diseases (STDs) in the United States support the continued need for and clinical development of Amphora® (L-lactic acid, citric acid, and potassium bitartrate) vaginal gel for the prevention of Chlamydia trachomatis and Neisseria gonorrhea in women.
The CDC reported this week at the National STD Prevention Conference in Washington that rates of syphilis, gonorrhea and chlamydia have climbed for the fourth consecutive year in the United States. Last year, nearly 2.3 million U.S. cases of these STDs were diagnosed, according to preliminary data, an increase of over 200,000 cases as compared with 2016.1
Amphora is being studied as an on-demand vaginal contraceptive and for the prevention of certain STDs. Evofem is conducting a Phase 2b double-blinded placebo-controlled efficacy trial (AMPREVENCE) to evaluate Amphora for the prevention of urogenital acquisition of Chlamydia trachomatis (primary endpoint) and Neisseria gonorrhea (secondary endpoint) in women. This clinical trial is actively enrolling 844 women at up to 50 centers in the United States for a four-month interventional period and subsequent one-month follow-up period.
Earlier this year, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for Amphora for the prevention of urogenital chlamydia in women. Fast Track designation is designed to facilitate the development and expedite the review of new therapies to treat serious conditions and fill unmet medical needs.
"As the prevalence of sexually transmitted diseases continues to rise, there is an increasing need for preventive measures. We believe the AMPREVENCE trial will provide data in support of Amphora's use to prevent these infections in women," said Kelly Culwell, MD, Chief Medical Officer of Evofem Biosciences. "With the growing epidemic of STDs, and chlamydia in particular, we have the potential to address a significant unmet medical need with a preventative therapeutic."
The Company expects to report top-line data by year-end 2018 from its confirmatory Phase 3 clinical trial of Amphora for contraception. Assuming positive results, Evofem expects to re-submit the Amphora New Drug Application (NDA) in the first half of 2019 which, if approved by the FDA, would position the Company to commercialize Amphora as the first and only hormone-free, on-demand contraceptive drug in early 2020.
About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. Evofem is leveraging its proprietary Multi-purpose Prevention Technology vaginal gel to develop product candidates for multiple indications, including contraception, the prevention of urogenital transmission of chlamydia and gonorrhea in women, and recurrent bacterial vaginosis. For more information regarding Evofem, please visit www.evofem.com.
Forward-Looking Statements
Statements in this press release about Evofem's future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the Company's control. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in the Company's filings with the Securities and Exchange Commission (SEC), including its Quarterly Report for the period ended March 31, 2018, as filed with the SEC on Form 10-Q on May 14, 2018, and include but are not limited to the following: objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the Company intends, expects, projects, believes or anticipates will or may occur in the future; risks and uncertainties associated with market conditions; statements about the anticipated results of the Phase 3 clinical trial evaluating Amphora as a contraceptive and the Phase 2b clinical trial of Amphora to prevent urogenital acquisition of Chlamydia trachomatis and Neisseria gonorrhea in women, and any expected completion dates or general timing for these clinical trials; the Company's reliance on third parties to conduct its clinical trials, research and development and manufacturing; the availability of reimbursement from government authorities and health insurance companies for the Company's products; the impact of potential product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the Company's common stock, and the concentration of power in its stock ownership. Forward-looking statements in this press release are made as of the date of this press release, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Evofem's views as of any date subsequent to the date hereof.
1Centers for Disease Control and Prevention (2018): STD Preliminary Data Accessed August 2018.
Investor Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
O: 858-550-1900 x167
Media Contact
Sophia Ononye
RXMD
evofem@rxmedyn.com
O: (646) 599-8630
M: (917) 557-1909
https://evofem.investorroom.com/
Rise in Prevalence of STDs Reported by CDC Supports Continued Development of Novel Solutions, Like Evofem's Product in Development, Amphora®, for the Prevention of Chlamydia
Mittwoch, 29.08.2018 15:00 von PR Newswire
PR Newswire
SAN DIEGO, Aug. 29, 2018
SAN DIEGO, Aug. 29, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, believes that new data recently released by the Centers for Disease Control and Prevention (CDC) on the increasing rates of sexually transmitted diseases (STDs) in the United States support the continued need for and clinical development of Amphora® (L-lactic acid, citric acid, and potassium bitartrate) vaginal gel for the prevention of Chlamydia trachomatis and Neisseria gonorrhea in women.
The CDC reported this week at the National STD Prevention Conference in Washington that rates of syphilis, gonorrhea and chlamydia have climbed for the fourth consecutive year in the United States. Last year, nearly 2.3 million U.S. cases of these STDs were diagnosed, according to preliminary data, an increase of over 200,000 cases as compared with 2016.1
Amphora is being studied as an on-demand vaginal contraceptive and for the prevention of certain STDs. Evofem is conducting a Phase 2b double-blinded placebo-controlled efficacy trial (AMPREVENCE) to evaluate Amphora for the prevention of urogenital acquisition of Chlamydia trachomatis (primary endpoint) and Neisseria gonorrhea (secondary endpoint) in women. This clinical trial is actively enrolling 844 women at up to 50 centers in the United States for a four-month interventional period and subsequent one-month follow-up period.
Earlier this year, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for Amphora for the prevention of urogenital chlamydia in women. Fast Track designation is designed to facilitate the development and expedite the review of new therapies to treat serious conditions and fill unmet medical needs.
"As the prevalence of sexually transmitted diseases continues to rise, there is an increasing need for preventive measures. We believe the AMPREVENCE trial will provide data in support of Amphora's use to prevent these infections in women," said Kelly Culwell, MD, Chief Medical Officer of Evofem Biosciences. "With the growing epidemic of STDs, and chlamydia in particular, we have the potential to address a significant unmet medical need with a preventative therapeutic."
The Company expects to report top-line data by year-end 2018 from its confirmatory Phase 3 clinical trial of Amphora for contraception. Assuming positive results, Evofem expects to re-submit the Amphora New Drug Application (NDA) in the first half of 2019 which, if approved by the FDA, would position the Company to commercialize Amphora as the first and only hormone-free, on-demand contraceptive drug in early 2020.
About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. Evofem is leveraging its proprietary Multi-purpose Prevention Technology vaginal gel to develop product candidates for multiple indications, including contraception, the prevention of urogenital transmission of chlamydia and gonorrhea in women, and recurrent bacterial vaginosis. For more information regarding Evofem, please visit www.evofem.com.
Forward-Looking Statements
Statements in this press release about Evofem's future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the Company's control. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in the Company's filings with the Securities and Exchange Commission (SEC), including its Quarterly Report for the period ended March 31, 2018, as filed with the SEC on Form 10-Q on May 14, 2018, and include but are not limited to the following: objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the Company intends, expects, projects, believes or anticipates will or may occur in the future; risks and uncertainties associated with market conditions; statements about the anticipated results of the Phase 3 clinical trial evaluating Amphora as a contraceptive and the Phase 2b clinical trial of Amphora to prevent urogenital acquisition of Chlamydia trachomatis and Neisseria gonorrhea in women, and any expected completion dates or general timing for these clinical trials; the Company's reliance on third parties to conduct its clinical trials, research and development and manufacturing; the availability of reimbursement from government authorities and health insurance companies for the Company's products; the impact of potential product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the Company's common stock, and the concentration of power in its stock ownership. Forward-looking statements in this press release are made as of the date of this press release, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Evofem's views as of any date subsequent to the date hereof.
1Centers for Disease Control and Prevention (2018): STD Preliminary Data Accessed August 2018.
Investor Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
O: 858-550-1900 x167
Media Contact
Sophia Ononye
RXMD
evofem@rxmedyn.com
O: (646) 599-8630
M: (917) 557-1909
https://evofem.investorroom.com/
Antwort auf Beitrag Nr.: 58.568.483 von Stingrey am 30.08.18 09:47:32Unsere Rakete hat gezündet. Schönes Wochenende wünsche ich Dir.
Trading Spotlight
Antwort auf Beitrag Nr.: 58.585.148 von fypet am 31.08.18 17:06:17Hi Fypet,
Danke - dir ebenso.
Hab mich gestern von einem Grossteil evfm getrennt und in TrovaGene umgeschichtet
Beides Werte mit Turbobooster
Danke - dir ebenso.
Hab mich gestern von einem Grossteil evfm getrennt und in TrovaGene umgeschichtet
Beides Werte mit Turbobooster
Der Kurs ist im Höhenflug, was ist der Grund ???
SAN DIEGO, Sept. 21, 2018 /PRNewswire/ — Evofem Biosciences, Inc., (NASDAQ: EVFM)
Top line data are expected by year-end 2018 from Evofem’s single-arm, open-label Phase 3 clinical trial (AMP002) evaluating Amphora for the prevention of pregnancy. AMP002 enrolled approximately 1,400 women aged 18-35 who are at risk of pregnancy at 112 centers in the United States; enrollment was complete in February 2018. The primary endpoint of this study is pregnancy prevention over seven cycles of use. Assuming positive results, the Company plans to re-submit the Amphora New Drug Application (NDA) in the second quarter of 2019. If approved by the FDA, Evofem will commercialize Amphora in early 2020 as the first and only hormone-free, on-demand, woman-controlled birth control method.
Top line data are expected by year-end 2018 from Evofem’s single-arm, open-label Phase 3 clinical trial (AMP002) evaluating Amphora for the prevention of pregnancy. AMP002 enrolled approximately 1,400 women aged 18-35 who are at risk of pregnancy at 112 centers in the United States; enrollment was complete in February 2018. The primary endpoint of this study is pregnancy prevention over seven cycles of use. Assuming positive results, the Company plans to re-submit the Amphora New Drug Application (NDA) in the second quarter of 2019. If approved by the FDA, Evofem will commercialize Amphora in early 2020 as the first and only hormone-free, on-demand, woman-controlled birth control method.
EVFM bereitet sich für den nächsten positiven Schub vor.
Antwort auf Beitrag Nr.: 58.590.236 von Stingrey am 01.09.18 12:32:31Wie Du siehst ist das ende der Fahnenstange noch nicht erklommen.
Es könnte noch mal ein Rücksetzer geben nach stockta candle DOJI bearish vom 26.09.18
Die Chartanalysen sind ein Werkzeug das auch keine 100% aussage interpretieren
schlussendlich entscheidet der Markt, schöne Woche noch.
Es könnte noch mal ein Rücksetzer geben nach stockta candle DOJI bearish vom 26.09.18
Die Chartanalysen sind ein Werkzeug das auch keine 100% aussage interpretieren
schlussendlich entscheidet der Markt, schöne Woche noch.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| 0,00 | |
| +0,13 | |
| -0,60 | |
| -0,06 | |
| +25,00 | |
| +4,24 | |
| 0,00 | |
| 0,00 | |
| -2,23 | |
| 0,00 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 48 | ||
| 44 | ||
| 29 | ||
| 21 | ||
| 17 | ||
| 17 | ||
| 13 | ||
| 12 | ||
| 10 | ||
| 10 |
